title: Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism.
abstract: Eight patients with primary hypercholesterolemia were treated with probucol for 17 weeks. Plasma total cholesterol, low density lipoprotein (LDL)-cholesterol, and high density lipoprotein (HDL)-cholesterol decreased by 16.6, 15.0 and 25.7%, respectively, in response to probucol treatment. Plasma levels of apolipoprotein B and apolipoprotein A-I also decreased, while apolipoprotein A-II concentrations were unchanged. The decrease in HDL-cholesterol levels was associated with a reduction in HDL particle size. No changes in the plasma lecithin:cholesterol acyltransferase activity or mass occurred in response to probucol treatment. In contrast, a significant 25% increase in plasma cholesteryl ester and triglyceride transfer activity occurred following probucol treatment. There was a positive correlation (R = 0.94) between cholesterol ester and triglyceride transfer. We propose that the increase in lipid transfer activity may in part explain the changes in HDL concentration and size, as well as the previously reported effect probucol has on reducing atherosclerosis in animal models.
authors.affiliation: Department of Pharmacology and Cell Biophysics, University of Cincinnati.
authors.forename: J R
authors.initials: JR
authors.lastname: Wetterau
authors.forename: K A
authors.initials: KA
authors.lastname: Combs
authors.forename: H W
authors.initials: HW
authors.lastname: Albers
authors.forename: G
authors.initials: G
authors.lastname: Lamkin
authors.forename: E A
authors.initials: EA
authors.lastname: Stein
authors.forename: R L
authors.initials: RL
authors.lastname: Barnhart
authors.forename: E M
authors.initials: EM
authors.lastname: Chi
authors.forename: R L
authors.initials: RL
authors.lastname: Jackson
authors.forename: J A
authors.initials: JA
authors.lastname: Harmony
mesh_terms: D000368:Aged; D001053:Apolipoproteins / Q000187:drug effects; D002352:Carrier Proteins / Q000187:drug effects; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters / Q000097:blood; D005260:Female; D006023:Glycoproteins; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000187:drug effects*; D008075:Lipoproteins, HDL / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000187:drug effects; D011341:Probucol / Q000494:pharmacology* / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D002788:Cholesterol Esters; D006023:Glycoproteins; D008055:Lipids; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D014280:Triglycerides; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D011341:Probucol